Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited (NASDAQ:ATHE) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 167,300 shares, an increase of 12.6% from the December 31st total of 148,600 shares. Based on an average daily trading volume, of 64,600 shares, the days-to-cover ratio is presently 2.6 days. Approximately 2.0% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Maxim Group lifted their price objective on shares of Alterity Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday. Benchmark cut shares of Alterity Therapeutics from a “speculative buy” rating to a “hold” rating in a research note on Monday.

Alterity Therapeutics Price Performance

Shares of ATHE traded up $0.10 during trading hours on Monday, reaching $4.90. The stock had a trading volume of 406,278 shares, compared to its average volume of 1,334,143. Alterity Therapeutics has a 12 month low of $1.00 and a 12 month high of $5.87. The firm has a 50-day simple moving average of $2.78 and a 200 day simple moving average of $1.83.

Institutional Investors Weigh In On Alterity Therapeutics

A hedge fund recently raised its stake in Alterity Therapeutics stock. HB Wealth Management LLC increased its holdings in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 31,883 shares of the company’s stock after purchasing an additional 8,100 shares during the period. HB Wealth Management LLC owned approximately 0.44% of Alterity Therapeutics worth $110,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.